FAQ: HeartBeam Inc.'s Advancements in 3D ECG and Cardiac Monitoring Technology

What new patents has HeartBeam Inc. secured?

HeartBeam Inc. has secured two new U.S. patents that protect core technologies behind its compact, cable-free 3D ECG device and its rhythm analysis algorithm for identifying arrhythmias through continuous signal input.

How does HeartBeam’s 3D ECG device work?

The 3D ECG device uses chest and finger electrodes to collect high-fidelity signals in three non-coplanar directions, designed for on-demand symptom recording and 12-lead ECG synthesis, with its software currently under FDA review.

What is the significance of HeartBeam’s rhythm analysis algorithm?

The rhythm analysis algorithm works across cardiac monitoring systems to trigger targeted data collection during abnormal rhythm detection, enhancing diagnostic precision.

How many patents does HeartBeam currently hold?

HeartBeam holds 20 issued patents and has 34 additional filings, including 13 U.S. and 4 international-issued patents related to technology enablement.

What are HeartBeam’s future plans for its technology?

HeartBeam plans to incorporate AI capabilities into its technology for enhanced diagnostic accuracy, continuing to innovate in digital cardiac care.

Where can I find more information about HeartBeam Inc.?

For more information, visit www.HeartBeam.com or the company’s newsroom at https://ibn.fm/BEAT.

What is the VALID-ECG pivotal study?

The VALID-ECG pivotal study is the data backing HeartBeam’s software currently under FDA review, though the content does not provide specific details about the study itself.

How does HeartBeam’s technology benefit cardiac care?

HeartBeam’s technology enables portable, cable-free 12-lead ECG monitoring outside medical facilities, allowing physicians to identify cardiac health trends and acute conditions remotely, thus transforming cardiac care management.